CA2446074A1 - Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation - Google Patents
Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation Download PDFInfo
- Publication number
- CA2446074A1 CA2446074A1 CA002446074A CA2446074A CA2446074A1 CA 2446074 A1 CA2446074 A1 CA 2446074A1 CA 002446074 A CA002446074 A CA 002446074A CA 2446074 A CA2446074 A CA 2446074A CA 2446074 A1 CA2446074 A1 CA 2446074A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- carbonic anhydrase
- activator
- compound
- cyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003846 Carbonic anhydrases Human genes 0.000 title claims abstract 11
- 108090000209 Carbonic anhydrases Proteins 0.000 title claims abstract 11
- 239000012190 activator Substances 0.000 title claims 12
- 230000013016 learning Effects 0.000 title claims 3
- 230000015654 memory Effects 0.000 title claims 3
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 24
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 230000000694 effects Effects 0.000 claims abstract 7
- 230000019771 cognition Effects 0.000 claims abstract 5
- 230000033764 rhythmic process Effects 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 11
- -1 hydroxy, amino Chemical group 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000003947 ethylamines Chemical class 0.000 claims 1
- 230000003371 gabaergic effect Effects 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000028161 membrane depolarization Effects 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000006886 spatial memory Effects 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2744115A CA2744115A1 (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28772101P | 2001-05-02 | 2001-05-02 | |
| US60/287,721 | 2001-05-02 | ||
| PCT/US2002/013784 WO2002087423A2 (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2744115A Division CA2744115A1 (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2446074A1 true CA2446074A1 (fr) | 2002-11-07 |
| CA2446074C CA2446074C (fr) | 2011-09-06 |
Family
ID=23104047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2744115A Abandoned CA2744115A1 (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
| CA2446074A Expired - Lifetime CA2446074C (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2744115A Abandoned CA2744115A1 (fr) | 2001-05-02 | 2002-05-02 | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040235889A1 (fr) |
| EP (1) | EP1383497B1 (fr) |
| JP (1) | JP4824268B2 (fr) |
| AT (1) | ATE411019T1 (fr) |
| AU (1) | AU2002256422A1 (fr) |
| CA (2) | CA2744115A1 (fr) |
| DE (1) | DE60229371D1 (fr) |
| ES (1) | ES2314056T3 (fr) |
| WO (1) | WO2002087423A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858602B2 (en) * | 2000-10-16 | 2010-12-28 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| AU2005274875A1 (en) * | 2004-07-19 | 2006-02-23 | University Of Florida Research Foundation, Inc. | Methods and materials for treating mental illness |
| CA3006091A1 (fr) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Effets therapeutiques de bryostatines, bryologues et autres substances associees sur la perte de memoire induite par ischemie/accident vasculaire et blessure au cerveau |
| EP2121000B1 (fr) | 2007-02-09 | 2015-09-23 | Blanchette Rockefeller Neurosciences, Institute | Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales |
| WO2014152917A2 (fr) * | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | Ligands physiologiques pour gpr139 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| RO86393B1 (ro) * | 1983-04-19 | 1985-04-01 | Gheorghe Danila | Medicament cu actiune vasculo-trombocitara |
| WO1985003869A1 (fr) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Procede de traitement de troubles de la memoire chez les personnes agees |
| US5962498A (en) * | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
| US6043270A (en) * | 1986-06-11 | 2000-03-28 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators V |
| US5955501A (en) * | 1986-06-11 | 1999-09-21 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators O |
| US5891906A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
| US6080784A (en) * | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| US5220068A (en) * | 1986-09-25 | 1993-06-15 | Chinoin Gyogyszer - Es Vegyeszeti Termekek Gyara Rt. | Psychostimulant agent |
| HU207280B (en) * | 1986-09-25 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them |
| US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5072004A (en) * | 1990-12-31 | 1991-12-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthetic conversion of bryostatin 2 into bryostatin 1 |
| US5981165A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
| US5196447A (en) * | 1991-08-08 | 1993-03-23 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University | Neristatin 1 |
| US5359115A (en) * | 1992-03-26 | 1994-10-25 | Affymax Technologies, N.V. | Methods for the synthesis of phosphonate esters |
| US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| DE4232899C2 (de) * | 1992-09-30 | 1995-02-23 | Birkmayer Joerg Univ Prof Dr | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer |
| US5393897A (en) * | 1993-07-02 | 1995-02-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of spongistatins 5,7,8 and 9 |
| US5362899A (en) * | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| US5625232A (en) * | 1994-07-15 | 1997-04-29 | Texas Instruments Incorporated | Reliability of metal leads in high speed LSI semiconductors using dummy vias |
| WO1996015131A1 (fr) * | 1994-11-10 | 1996-05-23 | Pfizer Pharmaceuticals Inc. | Composes lactone macrocycliques et leur procede de production |
| US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
| RU2115653C1 (ru) * | 1995-12-27 | 1998-07-20 | Иркутский институт органической химии СО РАН | Комплексные соединения замещенных имидазолов, проявляющие антидотную и антигипоксантную активность |
| US6043283A (en) * | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
| WO1999012901A1 (fr) * | 1997-09-08 | 1999-03-18 | Georgetown University | 2-pyrrolidones substituees activateurs de pkc |
| US5972684A (en) * | 1997-11-25 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Carbonic anhydrase VIII |
| PT1073432E (pt) * | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| WO2000066617A1 (fr) * | 1999-04-30 | 2000-11-09 | The Nathan S. Kline Institute For Psychiatric Research | Methodes de traitement de demence neuronale associee a une atrophie |
| AU2001268216A1 (en) * | 2000-06-07 | 2001-12-17 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Controlling attention and memory by altering neuronal carbonic anhydrase activity |
| EP1278253B1 (fr) * | 2001-07-19 | 2013-05-08 | Greatbatch Ltd. | Composant isolant pour une cellule électrochimique |
| TW201207390A (en) * | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
-
2002
- 2002-05-02 EP EP02725885A patent/EP1383497B1/fr not_active Expired - Lifetime
- 2002-05-02 ES ES02725885T patent/ES2314056T3/es not_active Expired - Lifetime
- 2002-05-02 AU AU2002256422A patent/AU2002256422A1/en not_active Abandoned
- 2002-05-02 AT AT02725885T patent/ATE411019T1/de not_active IP Right Cessation
- 2002-05-02 DE DE60229371T patent/DE60229371D1/de not_active Expired - Fee Related
- 2002-05-02 WO PCT/US2002/013784 patent/WO2002087423A2/fr active Application Filing
- 2002-05-02 CA CA2744115A patent/CA2744115A1/fr not_active Abandoned
- 2002-05-02 JP JP2002584781A patent/JP4824268B2/ja not_active Expired - Fee Related
- 2002-05-02 CA CA2446074A patent/CA2446074C/fr not_active Expired - Lifetime
- 2002-05-02 US US10/476,459 patent/US20040235889A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002256422A1 (en) | 2002-11-11 |
| DE60229371D1 (de) | 2008-11-27 |
| JP4824268B2 (ja) | 2011-11-30 |
| JP2004535386A (ja) | 2004-11-25 |
| WO2002087423A2 (fr) | 2002-11-07 |
| ATE411019T1 (de) | 2008-10-15 |
| EP1383497A4 (fr) | 2005-12-14 |
| CA2744115A1 (fr) | 2002-11-07 |
| EP1383497B1 (fr) | 2008-10-15 |
| EP1383497A2 (fr) | 2004-01-28 |
| CA2446074C (fr) | 2011-09-06 |
| WO2002087423A3 (fr) | 2003-02-27 |
| US20040235889A1 (en) | 2004-11-25 |
| ES2314056T3 (es) | 2009-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2540966T3 (es) | Compuestos biocidas de boronoftalida | |
| CA2290918A1 (fr) | Derives bicycliques heteroaromatiques utiles comme agents anticancereux | |
| KR890701559A (ko) | 3-인돌피루브산 유도체 및 그의 제약 용도 | |
| PE20000556A1 (es) | Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla | |
| Sekhon | Metalloid compounds as drugs | |
| RU2005104418A (ru) | Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин | |
| DE69613365D1 (de) | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie | |
| CA2468552A1 (fr) | Nucleosides 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine et leurs utilisations | |
| HRP20050214B1 (hr) | Opis kristala za oralni äśvrsti lijek i oralni äśvrsti lijek za tretiranje disurije koji sadržava isti | |
| JPH09510202A (ja) | カルボン酸エステルを用いる胎児ヘモグロビンレベルの上昇 | |
| CA2485535A1 (fr) | Formulation pharmaceutique a liberation modifiee | |
| CA2446074A1 (fr) | Activateurs d'anhydrase carbonique ameliorant l'acquisition des connaissances et la memorisation | |
| CA2302568A1 (fr) | Procede, compositions et trousses servant a augmenter la biodisponibilite orale d'agents pharmaceutiques | |
| CA2321547A1 (fr) | Derives de l'indole et compositions medicales les renfermant | |
| CA2438509A1 (fr) | Utilisation de derives de cyclohexenone pour la preparation d'un medicament permettant de traiter la dysurie | |
| HK1077847A1 (en) | Natural antitumor or antiviral substances and use of the same | |
| CA2373634A1 (fr) | Analogues d'yperite d'isophosphoramide et utilisation de ceux-ci | |
| CA2643400A1 (fr) | Derives de la camptothecine et leurs utilisations | |
| KR920004387A (ko) | 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘 | |
| ATE161178T1 (de) | Pyrazolpyridine für die behandlung der anämie | |
| CA2437994A1 (fr) | Derives cristallins de nucleoside pyrimidique | |
| RU2005132004A (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен | |
| CA2392630A1 (fr) | 2-amino-5,6-dihalo-3,4-dihydroquinazolines dotees de proprietes de reduction de la numeration des thrombocytes | |
| MXPA01007705A (es) | Derivado de benzamida y medicamento que lo contiene. | |
| CA2438506A1 (fr) | Utilisation de derives de cyclohexenone dans la fabrication d'un medicament destine au traitement de complications diabetiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220502 |